The state Boards of Pharmacy have been lax in regulating the practices of compounding pharmacies, like the New England Community Center, Framingham, Mass., implicated in the fungal meningitis outbreak. Instead, most of their enforcement actions have concentrated on compliance with traditional pharmacy licensing, controlled substances, and other requirements, according to a congressional report issued Oct. 29 by Rep. Edward J. Markey (D-Mass.).
Get the latest industry news, event updates, and more from Managed healthcare Executive.
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
July 14th 2025Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
Read More